trending Market Intelligence /marketintelligence/en/news-insights/trending/S0nrch_aeGjcZ_TXbTvr7A2 content esgSubNav
In This List

GlaxoSmithKline wins patent suit against Vectura in UK court

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


GlaxoSmithKline wins patent suit against Vectura in UK court

Vectura Group PLC said a U.K. court voted in favor of GlaxoSmithKline PLC relating to a dispute on an agreement between the two companies.

The litigation pertains to certain additional patents under an August 2010 patent license and option agreement with GlaxoSmithKline.

U.K.-based Vectura said it was evaluating a future course of action, including an option to appeal, with its advisers.

Vectura expects the results of the U.K. lawsuits will not materially affect its other cases pending against GlaxoSmithKline in the U.S.

Vectura, which develops and markets products for airways-related diseases, had signed an agreement with Hikma Pharmaceuticals PLC in November to develop and commercialize generic versions of GlaxoSmithKline's Ellipta portfolio of respiratory therapies.